OSTX Stock Forecast: OS Therapies, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.80
−2.07% on the day

The median 12-month analyst price target for OS Therapies, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 23 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$42.0M
Ticker Nerd rank
23/ 100
Median analyst target
$7.00
Analysts covering
4
Revenue$0.0
Operating income−$8.6M
Net income−$8.6M
Free cash flow−$5.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.8%
1M
−36.3%
YTD
−42.6%
1Y
−50.4%
From 52W high
−64.2%
From 52W low
+17.9%
$0.68
$2.24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores OS Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
23/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Volatility
68
Value
57
Momentum
26
Growth
23
Revisions
21
Quality
13
Issuance
6

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

OSTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OSTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26OSTXHigh $13.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$6.00
Low
$7.00
Median
$13.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026Roth CapitalInitiatesBuy—
19 May 2026Lake StreetMaintainsBuy—
30 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
27 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
5 Feb 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
9 Dec 2025D. Boral CapitalMaintainsBuy—
5 Dec 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025D. Boral CapitalMaintainsBuy—
18 Nov 2025Lake StreetMaintainsBuy—
17 Nov 2025D. Boral CapitalMaintainsBuy—
10 Oct 2025D. Boral CapitalMaintainsBuy—
30 Sept 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025D. Boral CapitalMaintainsBuy—
2 Sept 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
20 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OSTX.

Market Radar

This page is one stock. Monday covers all of them.

OSTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

OSTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, OS Therapies, Inc. returned −50.4% against +6.9% for the S&P 500, dividends included.

OSTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26OSTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OSTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−291.4%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OS Therapies, Inc. has a market value of $42.0M and an enterprise value of $44.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$39.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$18.5M.

  • Shares outstanding: 45.3M.

  • forward P/E: 2.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • OS Therapies, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

OSTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OSTXOS Therapies, Inc.$42.0M23
BMEABiomea Fusion, Inc.$41.7M46
CRBPCorbus Pharmaceuticals Holdings, Inc.$42.4M12
ELTXElicio Therapeutics, Inc.$41.0M51
ELOXEloxx Pharmaceuticals, Inc.$43.1M18
SPROSpero Therapeutics, Inc.$43.2M32
ANVSAnnovis Bio, Inc.$44.1M16

Take a look at OSTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own OS Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about OSTX

What is the OSTX stock price forecast for 2026-2027?

The median 12-month analyst price target for OS Therapies, Inc. is $7, with estimates ranging from $6 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OSTX stock a buy right now?

Of the 4 analysts covering OS Therapies, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OS Therapies, Inc. 23 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OSTX?

As at 21 Nov 2026, OS Therapies, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will OSTX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $7, and Ticker Nerd's factor model ranks OS Therapies, Inc. 23 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OSTX stock forecast for 2030?

No analyst covering OS Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $13 over the next 12 months.

How has OSTX stock performed over the past year?

OS Therapies, Inc. returned -50.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OS Therapies, Inc. do?

OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2.

Company

About OS Therapies, Inc.

OS Therapies Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for osteosarcoma and other solid tumors. The company’s current work centers on oncology programs that aim to harness the immune system against cancers expressing HER2, including its lead immunotherapy candidate OST-HER2. OS Therapies also advances an antibody-drug conjugate platform designed to support targeted cancer therapy development. Its product pipeline is directed toward high-unmet-need cancers, particularly rare bone cancers and other HER2-related solid tumors. Based in Grasonville, Maryland, OS Therapies Inc. operates within the biotechnology sector as a development-stage company focused on investigational cancer treatments and platform technologies for future clinical use.

CEO Mr. Paul A. Romness M.P.H. · 4 employees · United States · https://ostherapies.com